Group One Trading, L.P. Immunovant, Inc. Transaction History

Group One Trading, L.P.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$25.1 - $31.61 $680,184 - $856,599	27,099 Added 84.93%	59,007 $1.56 Million
Q1 2024 May 10, 2024	SELL	$30.27 - $43.79 $3.2 Million - $4.62 Million	-105,599 Reduced 76.8%	31,908 $1.03 Million
Q4 2023 Feb 14, 2024	BUY	$31.31 - $44.19 $4.31 Million - $6.08 Million	137,507 New	137,507 $5.79 Million
Q2 2023 Aug 09, 2023	BUY	$14.2 - $23.75 $740,317 - $1.24 Million	52,135 Added 218.54%	75,991 $1.44 Million
Q1 2023 May 12, 2023	BUY	$15.27 - $19.72 $364,281 - $470,440	23,856 New	23,856 $370,000
Q3 2022 Nov 09, 2022	SELL	$3.93 - $6.37 $23,658 - $38,347	-6,020 Reduced 9.55%	57,027 $318,000
Q2 2022 Aug 11, 2022	BUY	$3.38 - $5.65 $20,067 - $33,544	5,937 Added 10.4%	63,047 $246,000
Q1 2022 May 12, 2022	SELL	$5.06 - $8.77 $137,551 - $238,403	-27,184 Reduced 32.25%	57,110 $315,000
Q4 2021 Feb 11, 2022	BUY	$7.33 - $9.32 $32,853 - $41,772	4,482 Added 5.62%	84,294 $718,000
Q3 2021 Nov 12, 2021	BUY	$7.01 - $11.37 $340,293 - $551,945	48,544 Added 155.25%	79,812 $694,000
Q2 2021 Aug 10, 2021	BUY	$9.4 - $16.85 $203,434 - $364,667	21,642 Added 224.83%	31,268 $331,000
Q1 2021 May 12, 2021	BUY	$13.08 - $49.6 $125,908 - $477,449	9,626 New	9,626 $154,000

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.